Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Feb 07, 2023 10:01pm
136 Views
Post# 35273468

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:British Columbia Securities Commission!!poof says, "If Rathjen was incompetent Carina wouldn't have been able to raise all the money it has,"

So, are you saying that Rathjen has deliberately underfunded Bioasis?

And it's not the number of deals, poof. If you give too much away, you carve the low prices in stone? It becomes your policy.

Poof, with deals, size matters!

So far, all I've seen are little itty-bitty wiggly deals.

And to think, TO THINK...

...that the Cresence EGF stuff took top place in Rathjen's promotional material for over a year now. Pages of it in the corporate presentation and only 2 pages about xB3!!!

It's bent, it's twisted, and there is nothing pro-Bioasis about it all.

If Rathjen's heart is with Carina, then that's where she should be. If she hasn't the heart to take care of Bioasis, then she should go. 

On March 11, it will be 4 years since Rathjen became CEO. On March 21, it will be 5 years as board chair.

The stock is at 3.5¢. Five years on top has resulted in this. It's not that it's not good enough. It's that it couldn't be any worse

We thought 17¢ was a failure. But, my goodness, 3.5¢ ??

I don't think I've ever seen a poster as off-message and as devoid of reality than poof.


<< Previous
Bullboard Posts
Next >>